Abstract
Measurement of insulin-like growth factor-1 (IGF-I) has utility for the diagnosis and management of growth disorders, but inter-assay comparison of results has been complicated by a multitude of reference standards, antibodies, detection methods, and pre-analytical preparation strategies. We developed a quantitative LC-MS method for intact IGF-I, which has advantages in throughput and complexity when compared to mass spectrometric approaches that rely on stable isotope dilution analysis of tryptic peptides. Since the method makes use of full-scan data, the assay was easily extended to provide quantitative measurement of IGF-II using the same assay protocol. The validated LC-MS assay for IGF-I and IGF-II provides accurate results across the pediatric and adult reference range and is suitable for clinical use.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Animals
-
Calibration
-
Child
-
Child, Preschool
-
Chromatography, Liquid
-
Humans
-
Insulin-Like Growth Factor Binding Protein 3 / metabolism
-
Insulin-Like Growth Factor I / metabolism*
-
Insulin-Like Growth Factor II / metabolism*
-
Linear Models
-
Luminescent Measurements
-
Mass Spectrometry / methods*
-
Middle Aged
-
Quality Control
-
Radioimmunoassay
-
Rats
-
Reference Values
-
Retrospective Studies
-
Young Adult
Substances
-
IGFBP3 protein, human
-
Insulin-Like Growth Factor Binding Protein 3
-
Insulin-Like Growth Factor I
-
Insulin-Like Growth Factor II
Grants and funding
Funding for this work was provided by Quest Diagnostics. The funders had no role in study design, data collection and analysis, or preparation of the manuscript. The manuscript was reviewed by IP attorneys before providing approval for publication. Patent rights for the methods used in this research have been applied for.